가족성 아밀로이드성 다발 신경장애 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 약제 클래스별, 투여 경로별, 치료 단계별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Global Familial Amyloid Polyneuropathy Market size was valued at USD 2.9 Billion in 2024 and is poised to grow from USD 3.14 Billion in 2025 to USD 11.67 Billion by 2033, growing at a CAGR of 8.15% during the forecast period (2026-2033).

The global familial amyloid polyneuropathy (FAP) market is primarily fueled by advancements in RNA interference (RNAi) and antisense oligonucleotide (ASO) therapies, which effectively target the underlying cause of the disease-transthyretin (TTR) protein production-rather than merely managing symptoms. This innovative approach has gained traction due to clinical studies showcasing improved neurological outcomes and disease stabilization, prompting widespread physician adoption. Enhanced regulatory support and increased healthcare investments are further driving market growth, resulting in better patient survival rates and enhanced quality of life. Additionally, the rising prevalence of genetic testing and early screening initiatives for hereditary transthyretin amyloidosis is facilitating earlier diagnoses, allowing timely access to targeted therapies, ultimately sustaining demand within the FAP market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Familial Amyloid Polyneuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Familial Amyloid Polyneuropathy Market Segments Analysis

Global familial amyloid polyneuropathy market is segmented by disease type, drug class, route of administration, treatment stage, distribution channel, end user and region. Based on disease type, the market is segmented into hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) and mixed phenotype (polyneuropathy with cardiomyopathy). Based on drug class, the market is segmented into gene silencing therapies, transthyretin (TTR) stabilizers, amyloid-targeting therapies and supportive & symptomatic therapies. Based on route of administration, the market is segmented into intravenous (IV), subcutaneous (SC) and oral. Based on treatment stage, the market is segmented into first-line therapy and subsequent-line therapy. Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics, ambulatory care centers and home healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Familial Amyloid Polyneuropathy Market

The growth of public and professional awareness regarding familial amyloid polyneuropathy significantly enhances clinical recognition, resulting in earlier diagnostic testing and the identification of affected individuals prior to the onset of irreversible nerve damage. This awareness expands the population of patients who can benefit from emerging therapeutic options, thereby sustaining demand for both diagnostic and treatment services within healthcare systems. Furthermore, it incentivizes healthcare providers to implement screening protocols, invest in specialized training, and launch patient education initiatives. Collectively, these efforts facilitate the broader adoption of existing therapies and the integration of new treatments into the market, ultimately improving patient outcomes.

Restraints in the Global Familial Amyloid Polyneuropathy Market

The exorbitant cost associated with approved therapies for familial amyloid polyneuropathy creates substantial financial obstacles for both patients and healthcare payers. These challenges often result in restricted reimbursement policies, postponed treatment starts, and limited acceptance in price-sensitive markets, hindering overall market growth. Providers may hesitate to prescribe costly treatments, patients might opt out of therapy altogether, and insurers may redirect funds toward alternative healthcare priorities. Moreover, the lack of generic options and the intricate manufacturing processes involved in producing biologics intensify pricing challenges, further limiting the broad adoption of these therapies within public and private healthcare systems.

Market Trends of the Global Familial Amyloid Polyneuropathy Market

The global familial amyloid polyneuropathy market is experiencing a significant upward trend driven by rapid advancements in genetic testing technologies. Innovations in next-generation sequencing and targeted gene panels are expediting the diagnostic process, allowing for the swift identification of pathogenic TTR mutations. This progress not only enhances clinicians' confidence in diagnostics but also facilitates earlier therapeutic interventions and personalized care plans. As awareness of the disease grows among primary care providers, referrals to specialized neurology and cardiology services are increasing, resulting in higher patient enrollment in clinical trials. This dynamic environment is bolstering the adoption of emerging disease-modifying treatments, ultimately fueling market growth through increased physician trust and payer support.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Familial Amyloid Polyneuropathy Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
• Mixed Phenotype (Polyneuropathy with Cardiomyopathy)

Global Familial Amyloid Polyneuropathy Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Gene Silencing Therapies
• Transthyretin (TTR) Stabilizers
• Amyloid-Targeting Therapies
• Supportive & Symptomatic Therapies

Global Familial Amyloid Polyneuropathy Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous (IV)
• Subcutaneous (SC)
• Oral

Global Familial Amyloid Polyneuropathy Market Size by Treatment Stage & CAGR (2026-2033)

• Market Overview
• First-Line Therapy
• Subsequent-Line Therapy

Global Familial Amyloid Polyneuropathy Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Familial Amyloid Polyneuropathy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Care Centers
• Home Healthcare

Global Familial Amyloid Polyneuropathy Market Size & CAGR (2026-2033)

• North America (Disease Type, Drug Class, Route of Administration, Treatment Stage, Distribution Channel, End User)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Treatment Stage, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Treatment Stage, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Treatment Stage, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Treatment Stage, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Alnylam Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BridgeBio Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations